Anticoagulation Guidelines for Non-Valvular Atrial Fibrillation
Risk Stratification and Anticoagulation
- The American College of Cardiology recommends using the CHA₂DS₂-VASc score to determine anticoagulation need, with oral anticoagulation recommended for scores ≥2, reasonable to omit for score 0, and individualized for score 1 1, 2, 3
- The CHA₂DS₂-VASc score includes points for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/TIA/thromboembolism history, vascular disease, age 65-74 years, and sex category - female 2, 4
- For patients with a CHA₂DS₂-VASc score ≥2, oral anticoagulation is mandatory, with options including direct oral anticoagulants (DOACs) such as apixaban, dabigatran, or rivaroxaban, or warfarin with a target INR of 2.0-3.0 1, 2, 3
Anticoagulant Selection and Dosing
- The American College of Cardiology recommends DOACs as first-line therapy for patients with non-valvular atrial fibrillation, due to their superior safety profiles and at least equivalent efficacy compared to warfarin 1, 3
- For patients with normal renal function, DOAC dosing options include apixaban 5 mg twice daily, dabigatran 150 mg twice daily, or rivaroxaban 20 mg once daily with an evening meal 1, 4
- For patients with end-stage chronic kidney disease or hemodialysis, warfarin is recommended with a target INR of 2.0-3.0 1, 2, 3
Special Populations and Critical Caveats
- The European Society of Cardiology recommends that oral anticoagulation be considered for most patients with a CHA₂DS₂-VASc score of 1, as the thromboembolic event rate approaches 1% per year 7
- For patients with prior stroke or TIA, oral anticoagulation is mandatory regardless of CHA₂DS₂-VASc score 1, 2, 3
- For patients with mechanical heart valves, warfarin is required with a target INR based on valve type and position, and DOACs are not recommended 1, 3, 4
Ongoing Management Requirements
- Periodic reevaluation of stroke and bleeding risks is required, as well as renal function monitoring at least annually for DOAC patients, and INR monitoring weekly during warfarin initiation and then monthly when stable 1, 2, 6
- Bridging with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) may be necessary for patients undergoing procedures, but many procedures can be performed without interrupting warfarin 1, 3, 5